Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence
January 19, 2024 07:30 ET
|
Optimi Health Corp.
Optimi Health granted amendment to its Health Canada Controlled Drugs and Substances Licence.
Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats
January 03, 2024 07:30 ET
|
Optimi Health Corp.
Optimi Health Granted Precursor Licence for 3,4-Methylenedioxyphenyl-2-propanone (“MDP2P”), the precursor used in the chemical synthesis of MDMA.
Beckley Academy Welcomes New Faculty for 2024 Psychedelic Therapy Practitioners Courses
December 14, 2023 09:00 ET
|
Beckley Academy
Beckley Academy Welcomes New Faculty for 2024 Psychedelic Therapy Practitioners Courses
Beckley Retreats Announces Expanded Scholarship Program, Alongside New Specialty Programs for Underserved Communities
December 11, 2023 11:27 ET
|
Beckley Retreats
Beckley Retreats Announces Expanded Scholarship Program, Alongside New Specialty Programs for Underserved Communities
Optimi Health and Sunshine Earth Labs Ltd. Forge Strategic Supply Agreement
December 07, 2023 07:30 ET
|
Optimi Health Corp.
Optimi Health and Sunshine Earth Labs Ltd. Forge Strategic Supply Agreement
Beckley Retreats Launches Signature Program for Personal Discovery and Transformation
November 28, 2023 09:00 ET
|
Beckley Retreats
NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Beckley Retreats, a psilocybin retreats and holistic wellbeing company, announced today the launch of its Signature Program for Personal Discovery and...
Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing
November 28, 2023 07:42 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health...
PharmAla Partners with Clariti Strategic Advisors™
November 08, 2023 08:55 ET
|
PharmAla Biotech
PharmAla signs long-term partnership with Clariti Strategic Partners as its investment banking and advisory firm
PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa
November 07, 2023 08:55 ET
|
PharmAla Biotech
PharmAla completes the historic first shipment of MDMA and Psilocybin to its Australian Joint Venture, Cortexa, for use in commercial patient treatments
Optimi Health Welcomes Dr. Preston A. Chase as New Chief Science Officer
November 07, 2023 07:30 ET
|
Optimi Health Corp.
Optimi Health Introduces New Chief Science Officer Dr. Preston A. Chase.